Literature DB >> 20007693

Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H.

Dennis J van de Wijngaart1, Michel Molier, Scott J Lusher, Remko Hersmus, Guido Jenster, Jan Trapman, Hendrikus J Dubbink.   

Abstract

One mechanism of prostate tumors for escape from androgen ablation therapies is mutation of the androgen receptor (AR). We investigated the unique properties of the AR L701H mutant, which is strongly stimulated by cortisol, by a systematic structure-function analysis. Most amino acid substitutions at position 701 did not affect AR activation by 5alpha-dihydrotestosterone. Further analysis of the AR Leu(701) variants showed that AR L701M and AR L701Q, like AR L701H, had changed ligand responsiveness. AR L701M was strongly activated by progesterone but not by cortisol, whereas the opposite was observed for AR L701Q and AR L701H. Next, we analyzed a panel of structurally related steroids to study which of the OH groups at positions 11beta, 17alpha, and 21, which discriminate cortisol from progesterone, underlie the differential responses to both hormones. The results showed that the 17alpha-OH group was essential for activation of AR L701H and AR L701Q, whereas its absence was important for activation of AR L701M. Modeling indicated a conserved H-bonding network involving the steroidal 17alpha-OH group, His(701) or Gln(701), and the backbone of Ser(778). This network is absent in Leu(701) and in other mutants. A hydrophobic leucine or methionine at position 701 is unfavorable for the 17alpha-OH group. Our results indicate that the specific amino acid residue at position 701, its interaction with the backbone of Ser(778), and the steroidal 17alpha-hydroxyl group of the ligand are all important for the distinct transcriptional responses to progesterone and cortisol of AR mutants, including the prostate cancer mutant L701H.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20007693      PMCID: PMC2836112          DOI: 10.1074/jbc.M109.039958

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations.

Authors:  P M Matias; P Donner; R Coelho; M Thomaz; C Peixoto; S Macedo; N Otto; S Joschko; P Scholz; A Wegg; S Bäsler; M Schäfer; U Egner; M A Carrondo
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

2.  Collocation of androgen receptor gene mutations in prostate cancer.

Authors:  G Buchanan; N M Greenberg; H I Scher; J M Harris; V R Marshall; W D Tilley
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

3.  Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor.

Authors:  X Y Zhao; P J Malloy; A V Krishnan; S Swami; N M Navone; D M Peehl; D Feldman
Journal:  Nat Med       Date:  2000-06       Impact factor: 53.440

4.  Androgen receptor mutations in prostate cancer.

Authors:  M Marcelli; M Ittmann; S Mariani; R Sutherland; R Nigam; L Murthy; Y Zhao; D DiConcini; E Puxeddu; A Esen; J Eastham; N L Weigel; D J Lamb
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

5.  Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone.

Authors:  J S Sack; K F Kish; C Wang; R M Attar; S E Kiefer; Y An; G Y Wu; J E Scheffler; M E Salvati; S R Krystek; R Weinmann; H M Einspahr
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

6.  Novel molecular defects in the androgen receptor gene of Mexican patients with androgen insensitivity.

Authors:  B Chávez; F Vilchis; J C Zenteno; F Larrea; S Kofman-Alfaro
Journal:  Clin Genet       Date:  2001-03       Impact factor: 4.438

7.  Specific recognition of androgens by their nuclear receptor. A structure-function study.

Authors:  N Poujol; J M Wurtz; B Tahiri; S Lumbroso; J C Nicolas; D Moras; C Sultan
Journal:  J Biol Chem       Date:  2000-08-04       Impact factor: 5.157

8.  Phenotypic features, androgen receptor binding, and mutational analysis in 278 clinical cases reported as androgen insensitivity syndrome.

Authors:  S F Ahmed; A Cheng; L Dovey; J R Hawkins; H Martin; J Rowland; N Shimura; A D Tait; I A Hughes
Journal:  J Clin Endocrinol Metab       Date:  2000-02       Impact factor: 5.958

9.  Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.

Authors:  Emily B Askew; Robert T Gampe; Thomas B Stanley; Jonathan L Faggart; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2007-06-25       Impact factor: 5.157

10.  Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression.

Authors:  G N Brooke; M G Parker; C L Bevan
Journal:  Oncogene       Date:  2007-11-26       Impact factor: 9.867

View more
  18 in total

Review 1.  Role of steroid receptor and coregulator mutations in hormone-dependent cancers.

Authors:  Anna C Groner; Myles Brown
Journal:  J Clin Invest       Date:  2017-04-03       Impact factor: 14.808

2.  Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation.

Authors:  Hongli Liu; Rui Han; Jiazhong Li; Huanxiang Liu; Lifang Zheng
Journal:  J Comput Aided Mol Des       Date:  2016-11-15       Impact factor: 3.686

Review 3.  Bioinformatics and variability in drug response: a protein structural perspective.

Authors:  Jennifer L Lahti; Grace W Tang; Emidio Capriotti; Tianyun Liu; Russ B Altman
Journal:  J R Soc Interface       Date:  2012-05-02       Impact factor: 4.118

Review 4.  Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.

Authors:  Yundong He; Weidong Xu; Yu-Tian Xiao; Haojie Huang; Di Gu; Shancheng Ren
Journal:  Signal Transduct Target Ther       Date:  2022-06-24

Review 5.  Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.

Authors:  Philip A Watson; Vivek K Arora; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2015-11-13       Impact factor: 60.716

Review 6.  Drug discovery in advanced prostate cancer: translating biology into therapy.

Authors:  Timothy A Yap; Alan D Smith; Roberta Ferraldeschi; Bissan Al-Lazikani; Paul Workman; Johann S de Bono
Journal:  Nat Rev Drug Discov       Date:  2016-07-22       Impact factor: 84.694

7.  Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids.

Authors:  Jenny A Visser; Johannes Hofland; Gido Snaterse; Rosinda Mies; Wytske M van Weerden; Pim J French; Johan W Jonker; Adriaan B Houtsmuller; Martin E van Royen
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-01-19       Impact factor: 5.455

8.  Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.

Authors:  Alexander W Wyatt; Arun A Azad; Stanislav V Volik; Matti Annala; Kevin Beja; Brian McConeghy; Anne Haegert; Evan W Warner; Fan Mo; Sonal Brahmbhatt; Robert Shukin; Stephane Le Bihan; Martin E Gleave; Matti Nykter; Colin C Collins; Kim N Chi
Journal:  JAMA Oncol       Date:  2016-12-01       Impact factor: 31.777

Review 9.  Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer.

Authors:  Fabrizio Fontana; Patrizia Limonta
Journal:  Cells       Date:  2021-05-07       Impact factor: 6.600

Review 10.  Targeting molecular resistance in castration-resistant prostate cancer.

Authors:  Thenappan Chandrasekar; Joy C Yang; Allen C Gao; Christopher P Evans
Journal:  BMC Med       Date:  2015-09-01       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.